## Anthrax: Overview for Healthcare Providers

### Organism

*Bacillus anthracis* is a large, gram-positive, encapsulated, spore-forming, nonmotile rod.

### Reporting to Public Health

Suspected or confirmed cases require immediate notification to the local health department (LHD). See [www.vdh.virginia.gov/LHD/index.htm](http://www.vdh.virginia.gov/LHD/index.htm).

### Infectious Dose

- **Cutaneous**: A few spores may cause infection.
- **Inhalation**: As few as 1 to 3 spores may cause infection.
- **Gastrointestinal**: Unknown

### Occurrence

Worldwide, especially in agricultural regions in Central and South America, sub-Saharan Africa, central and southwestern Asia, southern and eastern Europe and the Caribbean. ~95% of naturally-acquired infections in the world are cutaneous form. In US, 1–2 cases reported annually.

### Natural Reservoir

Primary reservoirs are herbivores (e.g., livestock and wildlife herbivores). Spores can remain dormant in contaminated soil for decades.

### Route of Infection

- **Cutaneous**: Contact via break in skin (especially, arms, hands, face, neck)
- **Inhalation**: Inhalation of spores
- **Gastrointestinal**: Ingestion of contaminated meat from diseased animals

### Communicability

Person-to-person transmission is very rare and has only rarely been reported for cutaneous anthrax via direct contact with lesions.

### Case-fatality Rate

- **Cutaneous**: <1% with treatment; 20 % without treatment
- **Inhalation**: ~ 75% with treatment; 97% without treatment
- **Gastrointestinal**: Unknown with treatment; 25%–60% without treatment

### Risk Factors

Those at increased risk include persons who process animal products (e.g., hides, wool, hair, bone) from endemic areas, veterinarians, laboratorians, livestock producers, those who eat undercooked meat in endemic areas, heroin-injecting drug users; if bioterrorism, mail handlers, military personnel or other responders.

### Incubation period

- **Cutaneous**: 1–7 days (1–12 days)
- **Inhalation**: 2–60 days or longer (2001 outbreak: 4–6 days)
- **Gastrointestinal**: 2–5 days (range 1–7 days)

### Clinical Manifestations

- **Cutaneous**: Infection begins as a small papule or vesicle that ulcerates with central necrosis and drying. Painless, localized nonpitting edema surrounds the ulcerated area, which progresses to a dark, leathery eschar. Extensive nonpitting edema, regional lymphadenopathy, lymphangitis, fever, and malaise may be present. Lesions tend to occur on exposed areas of the body (e.g., face, hands, arms, neck).
- **Inhalation**: Phase 1: Nonspecific, including fever, nonproductive cough, fatigue, myalgias, sweats, chest discomfort
  - Phase 2: Occurs after 1–3 days of improvement after Phase 1, with abrupt onset of high fever and severe respiratory distress (dyspnea, stridor, cyanosis); shock and death occurs within 24–36 hours at Phase 2.
- **Gastrointestinal**: Intestinal form is manifested with nausea, vomiting, anorexia and fever, followed by severe abdominal pain, bloody diarrhea, vomiting of blood, and signs of septicemia.
  - Oropharyngeal form is rare, manifested with dysphagia and posterior oropharyngeal necrotic ulcers, fever, sepsis, and bilateral neck swelling.
  - GI tract ulcers may cause hemorrhage, obstruction or perforation

### Differential diagnosis

- **Cutaneous**: Brown recluse spider bite, staphylococcal or streptococcal cellulitis, vasculitides, bubonic plague, necrotizing soft tissue infections, orf, necrotic herpes simplex infection; ulceroglandular tularemia, scrub typhus, rickettsial spotted fevers, rat bite fever,
- **Inhalation**: Mycoplasmal pneumonia, Legionnaires' disease, psittacosis, tularemia, viral pneumonia, Q fever, histoplasmosis, coccidiomycosis, acute bacterial mediastinitis, tuberculosis
- **Gastrointestinal**: Intestinal form: typhoid fever, intestinal tularemia, bacterial perforitis
  - Oropharyngeal form: diphtheria, streptococcal pharyngitis, enteroviral vesicular pharyngitis, acute herpetic pharyngitis, *Yersinia enterocolitica*
## Anthrax: Overview for Healthcare Providers (Dec 2014)

VDH/OEPI/DSI

For additional guidance, refer to CDC guidance at [http://www.cdc.gov/anthrax/](http://www.cdc.gov/anthrax/).

<table>
<thead>
<tr>
<th>Cutaneous</th>
<th>Inhalation</th>
<th>Gastrointestinal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Laboratory tests/Sample collection</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- If systemic symptoms present, blood cultures (before start antimicrobial therapy)</td>
<td>- Blood cultures (before antimicrobial therapy)</td>
<td>- Blood cultures (before start antibiotics)</td>
</tr>
<tr>
<td>- Swab vesicle/eschar/ulcer (2 dry cotton swabs per site: 1 for culture, 1 for PCR)</td>
<td>- Blood (10mL in EDTA or sodium citrate tubes) for PCR</td>
<td>- Blood (10mL in EDTA or sodium citrate tubes) for PCR</td>
</tr>
<tr>
<td>- Full thickness punch biopsy of papule or vesicle including adjacent skin</td>
<td>- Pleural fluid, if present, for culture, PCR and anthrax lethal toxin testing</td>
<td>- Ascites fluid for culture, PCR and anthrax lethal toxin testing</td>
</tr>
<tr>
<td>- If on antibiotics &lt;24 hours, 2nd biopsy for culture and PCR</td>
<td>- Plural and/or bronchial biopsies for immunohistochemistry (IHC)</td>
<td>- Oropharyngeal form: 2 sterile moist swabs (1 for culture and 1 for PCR) of suspected lesions in the oropharynx or buccal cavity, or on the tongue, tonsils or posterior pharyngeal wall</td>
</tr>
<tr>
<td>- Acute serum for anthrax lethal toxin testing and acute and convalescent serum samples for serologic testing</td>
<td>- Acute serum for anthrax lethal toxin testing and acute and convalescent serum samples for serologic testing</td>
<td>- Intestinal form: rectal swab (using sterile dry swab) and/or an aseptically collected stool (collect 2 separate swabs per site: 1 for culture, 1 for PCR)</td>
</tr>
<tr>
<td></td>
<td>- If fatal case, autopsy tissues for histopathology, special stains, and IHC</td>
<td>- Acute and convalescent serum samples for serologic testing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If fatal case, autopsy tissues for histopathology, special stains, and IHC</td>
</tr>
</tbody>
</table>

If anthrax is suspected, notify LHD immediately to discuss the case and laboratory testing. Specimens should be sent to Division of Consolidated Laboratory Services (DCLS) after LHD has been consulted and testing has been approved by LHD/DCLS. The DCLS Emergency Duty Officer can be reached 24/7 at (804) 335-4617.

### Treatment

Drugs most often recommended for treatment are ciprofloxacin or doxycycline. Information on preferred drugs, dosing and duration of treatment can be found at [http://www.cdc.gov/anthrax/](http://www.cdc.gov/anthrax/). For additional information on dosing, please consult the package inserts.

### Postexposure Prophylaxis

Exposed individuals should receive a full 60-day prophylaxis treatment regardless of anthrax vaccination status. Information on preferred drugs, dosing and duration of prophylaxis can be found at [http://www.cdc.gov/anthrax/](http://www.cdc.gov/anthrax/). For additional information on dosing, please consult the package inserts.

### Infection Control

Use standard precautions; for patients with draining cutaneous wounds, add contact precautions.

### Vaccine

There is a vaccine licensed to prevent anthrax, but it is not typically available for the general public. Anthrax Vaccine Adsorbed (AVA) protects against cutaneous and inhalation anthrax and is approved by FDA for at-risk adults before exposure to anthrax. At-risk individuals include people who work with imported animal hides or furs, handle animal products in high-risk areas, work with anthrax in a lab, have repeated exposures to anthrax spores, or are military personnel who work in areas where anthrax could be used as a bioterrorism weapon. Currently, FDA has not approved the vaccine for use after exposure for anyone. If there was an emergency, people who were exposed might be given vaccine to help prevent disease under a special protocol for use of the vaccine during emergencies.